CA2408105A1 - Novel proteases - Google Patents

Novel proteases Download PDF

Info

Publication number: CA2408105A1
Authority: CA; Canada
Prior art keywords: seq; protease; polypeptide; nucleic acid; group
Prior art date: 2000-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002408105A

Other languages

English (en)

French (fr)

Inventor

Gregory D. Plowman

David Whyte

Sucha Sudarsanam

Gerard Manning

Sean Caenepeel

Vilia Ann Payne

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sugen LLC

Pharmacia LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-04

Filing date

2001-05-04

Publication date

2001-11-08

2001-05-04 Application filed by Individual filed Critical Individual

2001-11-08 Publication of CA2408105A1 publication Critical patent/CA2408105A1/en

Status Abandoned legal-status Critical Current

Links

108091005804 Peptidases Proteins 0.000 title claims abstract description 375
239000004365 Protease Substances 0.000 title claims abstract description 332
102000035195 Peptidases Human genes 0.000 title description 344
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 300
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 269
229920001184 polypeptide Polymers 0.000 claims abstract description 251
238000000034 method Methods 0.000 claims abstract description 177
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 89
201000010099 disease Diseases 0.000 claims abstract description 60
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 51
238000011282 treatment Methods 0.000 claims abstract description 15
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 21
210000004027 cell Anatomy 0.000 claims description 214
150000007523 nucleic acids Chemical class 0.000 claims description 149
102000039446 nucleic acids Human genes 0.000 claims description 123
108020004707 nucleic acids Proteins 0.000 claims description 123
230000000694 effects Effects 0.000 claims description 83
230000027455 binding Effects 0.000 claims description 68
125000003275 alpha amino acid group Chemical group 0.000 claims description 59
239000000523 sample Substances 0.000 claims description 54
239000002773 nucleotide Substances 0.000 claims description 50
125000003729 nucleotide group Chemical group 0.000 claims description 50
238000003556 assay Methods 0.000 claims description 46
206010028980 Neoplasm Diseases 0.000 claims description 41
239000000126 substance Substances 0.000 claims description 39
238000012360 testing method Methods 0.000 claims description 38
239000013598 vector Substances 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 30
208000035475 disorder Diseases 0.000 claims description 29
238000009396 hybridization Methods 0.000 claims description 29
241000282414 Homo sapiens Species 0.000 claims description 28
230000000295 complement effect Effects 0.000 claims description 26
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 21
239000002853 nucleic acid probe Substances 0.000 claims description 21
230000003993 interaction Effects 0.000 claims description 20
210000004556 brain Anatomy 0.000 claims description 18
238000013518 transcription Methods 0.000 claims description 18
230000035897 transcription Effects 0.000 claims description 18
238000001514 detection method Methods 0.000 claims description 16
208000024172 Cardiovascular disease Diseases 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 13
210000001072 colon Anatomy 0.000 claims description 12
210000004408 hybridoma Anatomy 0.000 claims description 12
208000030159 metabolic disease Diseases 0.000 claims description 12
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
230000009870 specific binding Effects 0.000 claims description 11
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
210000000481 breast Anatomy 0.000 claims description 9
208000037765 diseases and disorders Diseases 0.000 claims description 9
210000003734 kidney Anatomy 0.000 claims description 9
230000001537 neural effect Effects 0.000 claims description 9
206010020772 Hypertension Diseases 0.000 claims description 8
210000004072 lung Anatomy 0.000 claims description 8
208000012661 Dyskinesia Diseases 0.000 claims description 7
208000001953 Hypotension Diseases 0.000 claims description 7
208000019695 Migraine disease Diseases 0.000 claims description 7
208000019022 Mood disease Diseases 0.000 claims description 7
208000002193 Pain Diseases 0.000 claims description 7
208000028017 Psychotic disease Diseases 0.000 claims description 7
201000001880 Sexual dysfunction Diseases 0.000 claims description 7
208000010877 cognitive disease Diseases 0.000 claims description 7
230000003394 haemopoietic effect Effects 0.000 claims description 7
230000036543 hypotension Effects 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
230000002611 ovarian Effects 0.000 claims description 7
231100000872 sexual dysfunction Toxicity 0.000 claims description 7
208000012902 Nervous system disease Diseases 0.000 claims description 6
208000025966 Neurological disease Diseases 0.000 claims description 6
208000015114 central nervous system disease Diseases 0.000 claims description 6
208000027232 peripheral nervous system disease Diseases 0.000 claims description 6
230000008859 change Effects 0.000 claims description 5
238000000338 in vitro Methods 0.000 claims description 4
239000013642 negative control Substances 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
238000012544 monitoring process Methods 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
201000005787 hematologic cancer Diseases 0.000 claims 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
230000000926 neurological effect Effects 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 195
102000004169 proteins and genes Human genes 0.000 abstract description 130
238000003745 diagnosis Methods 0.000 abstract description 3
235000019419 proteases Nutrition 0.000 description 236
235000018102 proteins Nutrition 0.000 description 109
150000001875 compounds Chemical class 0.000 description 102
230000014509 gene expression Effects 0.000 description 55
108020004414 DNA Proteins 0.000 description 54
108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
230000006870 function Effects 0.000 description 36
229940024606 amino acid Drugs 0.000 description 35
239000003446 ligand Substances 0.000 description 34
235000001014 amino acid Nutrition 0.000 description 33
150000001413 amino acids Chemical class 0.000 description 33
235000019833 protease Nutrition 0.000 description 28
239000003795 chemical substances by application Substances 0.000 description 27
210000001519 tissue Anatomy 0.000 description 27
102000004190 Enzymes Human genes 0.000 description 26
108090000790 Enzymes Proteins 0.000 description 26
229940088598 enzyme Drugs 0.000 description 26
241001465754 Metazoa Species 0.000 description 25
239000000203 mixture Substances 0.000 description 25
102000005741 Metalloproteases Human genes 0.000 description 23
108010006035 Metalloproteases Proteins 0.000 description 23
239000000758 substrate Substances 0.000 description 23
108091034117 Oligonucleotide Proteins 0.000 description 22
-1 aspartyl residue Chemical group 0.000 description 22
239000000243 solution Substances 0.000 description 22
230000003197 catalytic effect Effects 0.000 description 21
230000002159 abnormal effect Effects 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 20
108020004999 messenger RNA Proteins 0.000 description 20
230000004913 activation Effects 0.000 description 19
238000012545 processing Methods 0.000 description 19
239000000047 product Substances 0.000 description 18
230000019491 signal transduction Effects 0.000 description 18
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 17
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 17
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 17
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 17
230000001105 regulatory effect Effects 0.000 description 17
102000005927 Cysteine Proteases Human genes 0.000 description 16
108010005843 Cysteine Proteases Proteins 0.000 description 16
230000000692 anti-sense effect Effects 0.000 description 16
239000003814 drug Substances 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000012528 membrane Substances 0.000 description 16
240000004808 Saccharomyces cerevisiae Species 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 14
238000012546 transfer Methods 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
239000000074 antisense oligonucleotide Substances 0.000 description 13
238000012230 antisense oligonucleotides Methods 0.000 description 13
239000000284 extract Substances 0.000 description 13
201000001320 Atherosclerosis Diseases 0.000 description 12
108090000994 Catalytic RNA Proteins 0.000 description 12
102000053642 Catalytic RNA Human genes 0.000 description 12
230000001413 cellular effect Effects 0.000 description 12
230000001684 chronic effect Effects 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 12
230000037361 pathway Effects 0.000 description 12
108091092562 ribozyme Proteins 0.000 description 12
238000012216 screening Methods 0.000 description 12
239000007787 solid Substances 0.000 description 12
230000002103 transcriptional effect Effects 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
230000000977 initiatory effect Effects 0.000 description 11
201000006417 multiple sclerosis Diseases 0.000 description 11
230000035772 mutation Effects 0.000 description 11
230000008569 process Effects 0.000 description 11
230000007017 scission Effects 0.000 description 11
238000013519 translation Methods 0.000 description 11
230000014616 translation Effects 0.000 description 11
239000002585 base Substances 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000002243 precursor Substances 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
208000024827 Alzheimer disease Diseases 0.000 description 9
102000004580 Aspartic Acid Proteases Human genes 0.000 description 9
108010017640 Aspartic Acid Proteases Proteins 0.000 description 9
108091026890 Coding region Proteins 0.000 description 9
108020004705 Codon Proteins 0.000 description 9
102000012479 Serine Proteases Human genes 0.000 description 9
108010022999 Serine Proteases Proteins 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
238000001415 gene therapy Methods 0.000 description 9
230000002068 genetic effect Effects 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
230000009261 transgenic effect Effects 0.000 description 9
108020000948 Antisense Oligonucleotides Proteins 0.000 description 8
102000011727 Caspases Human genes 0.000 description 8
108010076667 Caspases Proteins 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
241000196324 Embryophyta Species 0.000 description 8
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
108700039691 Genetic Promoter Regions Proteins 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
210000002744 extracellular matrix Anatomy 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
208000015122 neurodegenerative disease Diseases 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
206010039073 rheumatoid arthritis Diseases 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
206010004146 Basal cell carcinoma Diseases 0.000 description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
108010050254 Presenilins Proteins 0.000 description 7
102000015499 Presenilins Human genes 0.000 description 7
201000004681 Psoriasis Diseases 0.000 description 7
108090000783 Renin Proteins 0.000 description 7
102100028255 Renin Human genes 0.000 description 7
241000700605 Viruses Species 0.000 description 7
238000007792 addition Methods 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
230000033228 biological regulation Effects 0.000 description 7
239000006184 cosolvent Substances 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
238000013537 high throughput screening Methods 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000003834 intracellular effect Effects 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 6
102000001477 Deubiquitinating Enzymes Human genes 0.000 description 6
108010093668 Deubiquitinating Enzymes Proteins 0.000 description 6
102000003693 Hedgehog Proteins Human genes 0.000 description 6
108090000031 Hedgehog Proteins Proteins 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
208000022559 Inflammatory bowel disease Diseases 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
102000043136 MAP kinase family Human genes 0.000 description 6
108091054455 MAP kinase family Proteins 0.000 description 6
241000579835 Merops Species 0.000 description 6
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 6
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 6
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 6
108700008625 Reporter Genes Proteins 0.000 description 6
102100040247 Tumor necrosis factor Human genes 0.000 description 6
108090000848 Ubiquitin Proteins 0.000 description 6
102000044159 Ubiquitin Human genes 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000005784 autoimmunity Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
230000004927 fusion Effects 0.000 description 6
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
239000002502 liposome Substances 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
229910021645 metal ion Inorganic materials 0.000 description 6
229930014626 natural product Natural products 0.000 description 6
230000004770 neurodegeneration Effects 0.000 description 6
201000008482 osteoarthritis Diseases 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
210000002307 prostate Anatomy 0.000 description 6
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000029865 regulation of blood pressure Effects 0.000 description 6
206010039083 rhinitis Diseases 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
208000019901 Anxiety disease Diseases 0.000 description 5
239000004475 Arginine Substances 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
208000020925 Bipolar disease Diseases 0.000 description 5
108010032088 Calpain Proteins 0.000 description 5
102000007590 Calpain Human genes 0.000 description 5
102000014914 Carrier Proteins Human genes 0.000 description 5
102100021633 Cathepsin B Human genes 0.000 description 5
206010053567 Coagulopathies Diseases 0.000 description 5
206010011091 Coronary artery thrombosis Diseases 0.000 description 5
230000004568 DNA-binding Effects 0.000 description 5
206010012218 Delirium Diseases 0.000 description 5
206010012289 Dementia Diseases 0.000 description 5
102000005593 Endopeptidases Human genes 0.000 description 5
108010059378 Endopeptidases Proteins 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
208000010412 Glaucoma Diseases 0.000 description 5
244000060234 Gmelina philippensis Species 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
241000713340 Human immunodeficiency virus 2 Species 0.000 description 5
208000023105 Huntington disease Diseases 0.000 description 5
102000001399 Kallikrein Human genes 0.000 description 5
108060005987 Kallikrein Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
208000008589 Obesity Diseases 0.000 description 5
208000022873 Ocular disease Diseases 0.000 description 5
108090000526 Papain Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
208000017442 Retinal disease Diseases 0.000 description 5
206010038923 Retinopathy Diseases 0.000 description 5
208000036623 Severe mental retardation Diseases 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
208000000323 Tourette Syndrome Diseases 0.000 description 5
208000016620 Tourette disease Diseases 0.000 description 5
206010052779 Transplant rejections Diseases 0.000 description 5
241000251539 Vertebrata <Metazoa> Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000004075 alteration Effects 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000003321 amplification Effects 0.000 description 5
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
230000036506 anxiety Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
208000006673 asthma Diseases 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
208000028683 bipolar I disease Diseases 0.000 description 5
210000002459 blastocyst Anatomy 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
208000002528 coronary thrombosis Diseases 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000007876 drug discovery Methods 0.000 description 5
210000002257 embryonic structure Anatomy 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
230000012010 growth Effects 0.000 description 5
208000037824 growth disorder Diseases 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
208000002780 macular degeneration Diseases 0.000 description 5
210000001161 mammalian embryo Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000000520 microinjection Methods 0.000 description 5
206010027599 migraine Diseases 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
235000020824 obesity Nutrition 0.000 description 5
229940055729 papain Drugs 0.000 description 5
235000019834 papain Nutrition 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
210000001236 prokaryotic cell Anatomy 0.000 description 5
230000002797 proteolythic effect Effects 0.000 description 5
230000010410 reperfusion Effects 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
201000000980 schizophrenia Diseases 0.000 description 5
241000894007 species Species 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
210000003932 urinary bladder Anatomy 0.000 description 5
238000005406 washing Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
101710150192 Beta-secretase 1 Proteins 0.000 description 4
102000005367 Carboxypeptidases Human genes 0.000 description 4
108010006303 Carboxypeptidases Proteins 0.000 description 4
101800001224 Disintegrin Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
108010067372 Pancreatic elastase Proteins 0.000 description 4
102000016387 Pancreatic elastase Human genes 0.000 description 4
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
102100038358 Prostate-specific antigen Human genes 0.000 description 4
241000700159 Rattus Species 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
239000004473 Threonine Substances 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
206010054094 Tumour necrosis Diseases 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006555 catalytic reaction Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000013461 design Methods 0.000 description 4
210000001900 endoderm Anatomy 0.000 description 4
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000007788 liquid Substances 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
210000004940 nucleus Anatomy 0.000 description 4
210000000578 peripheral nerve Anatomy 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
230000011664 signaling Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
230000007838 tissue remodeling Effects 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
238000010396 two-hybrid screening Methods 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 3
102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 3
241000193830 Bacillus <bacterium> Species 0.000 description 3
102100021257 Beta-secretase 1 Human genes 0.000 description 3
241000283707 Capra Species 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
108090000712 Cathepsin B Proteins 0.000 description 3
102000004178 Cathepsin E Human genes 0.000 description 3
108090000611 Cathepsin E Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 3
101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 3
108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 3
102000035100 Threonine proteases Human genes 0.000 description 3
108091005501 Threonine proteases Proteins 0.000 description 3
108090000190 Thrombin Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
238000002820 assay format Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000008298 dragée Substances 0.000 description 3
230000013020 embryo development Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
208000028653 esophageal adenocarcinoma Diseases 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
235000014304 histidine Nutrition 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000004844 protein turnover Effects 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000022983 regulation of cell cycle Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
238000001890 transfection Methods 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
239000006226 wash reagent Substances 0.000 description 3
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 2
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 2
SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
108091022885 ADAM Proteins 0.000 description 2
102000029791 ADAM Human genes 0.000 description 2
229920000178 Acrylic resin Polymers 0.000 description 2
239000004925 Acrylic resin Substances 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102400000344 Angiotensin-1 Human genes 0.000 description 2
101800000734 Angiotensin-1 Proteins 0.000 description 2
102400000345 Angiotensin-2 Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
108020004491 Antisense DNA Proteins 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000304886 Bacilli Species 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 2
101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108090000317 Chymotrypsin Proteins 0.000 description 2
102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 2
102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 2
101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
108090001081 Dipeptidases Proteins 0.000 description 2
102000004860 Dipeptidases Human genes 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
102000018389 Exopeptidases Human genes 0.000 description 2
108010091443 Exopeptidases Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
108010043026 HGF activator Proteins 0.000 description 2
102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
102100031465 Hepatocyte growth factor activator Human genes 0.000 description 2
101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 2
101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 2
101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 2
101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 2
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
102000007474 Multiprotein Complexes Human genes 0.000 description 2
108010085220 Multiprotein Complexes Proteins 0.000 description 2
102100034681 Myeloblastin Human genes 0.000 description 2
108090000973 Myeloblastin Proteins 0.000 description 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
241000051107 Paraechinus aethiopicus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108090000113 Plasma Kallikrein Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
102100034869 Plasma kallikrein Human genes 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
102000001938 Plasminogen Activators Human genes 0.000 description 2
108010001014 Plasminogen Activators Proteins 0.000 description 2
102100022036 Presenilin-2 Human genes 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 2
101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 2
101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 2
101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 2
101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
102000008847 Serpin Human genes 0.000 description 2
108050000761 Serpin Proteins 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
108700026226 TATA Box Proteins 0.000 description 2
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
241000204673 Thermoplasma acidophilum Species 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
206010064390 Tumour invasion Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000002788 anti-peptide Effects 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000003816 antisense DNA Substances 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
238000003287 bathing Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
229940019700 blood coagulation factors Drugs 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000009400 cancer invasion Effects 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229960002376 chymotrypsin Drugs 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000006854 communication Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
229940066758 endopeptidases Drugs 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
229960005051 fluostigmine Drugs 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000000762 glandular Effects 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
210000004349 growth plate Anatomy 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
150000002463 imidates Chemical class 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000002156 mixing Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
210000000276 neural tube Anatomy 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000011164 ossification Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001936 parietal effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000000059 patterning Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000013615 primer Substances 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
108010043524 protease E Proteins 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000002821 scintillation proximity assay Methods 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
239000003001 serine protease inhibitor Substances 0.000 description 2
210000000717 sertoli cell Anatomy 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000002023 somite Anatomy 0.000 description 2
230000021595 spermatogenesis Effects 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
108091007196 stromelysin Proteins 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000008685 targeting Effects 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
150000007970 thio esters Chemical class 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
QXABAINQWXBUFW-UHFFFAOYSA-N 3-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxypropanoic acid Chemical group OC(=O)C(O)CC1=CNC(=O)NC1=O QXABAINQWXBUFW-UHFFFAOYSA-N 0.000 description 1
ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical group CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical group BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical group ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical group IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
108091007505 ADAM17 Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
108091005508 Acid proteases Proteins 0.000 description 1
241000203809 Actinomycetales Species 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102100038778 Amphiregulin Human genes 0.000 description 1
108010033760 Amphiregulin Proteins 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
241000256844 Apis mellifera Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
102000009422 Aspartic endopeptidases Human genes 0.000 description 1
108030004804 Aspartic endopeptidases Proteins 0.000 description 1
102000035101 Aspartic proteases Human genes 0.000 description 1
108091005502 Aspartic proteases Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101150072353 CAPN3 gene Proteins 0.000 description 1
102000004631 Calcineurin Human genes 0.000 description 1
108010042955 Calcineurin Proteins 0.000 description 1
102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
102100029398 Calpain small subunit 1 Human genes 0.000 description 1
102100032537 Calpain-2 catalytic subunit Human genes 0.000 description 1
102100032539 Calpain-3 Human genes 0.000 description 1
102100030005 Calpain-6 Human genes 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
241000710190 Cardiovirus Species 0.000 description 1
102100035904 Caspase-1 Human genes 0.000 description 1
108090000426 Caspase-1 Proteins 0.000 description 1
102000003902 Cathepsin C Human genes 0.000 description 1
108090000267 Cathepsin C Proteins 0.000 description 1
102100032219 Cathepsin D Human genes 0.000 description 1
108090000258 Cathepsin D Proteins 0.000 description 1
102100025975 Cathepsin G Human genes 0.000 description 1
108090000617 Cathepsin G Proteins 0.000 description 1
108090000625 Cathepsin K Proteins 0.000 description 1
102000004171 Cathepsin K Human genes 0.000 description 1
108090000613 Cathepsin S Proteins 0.000 description 1
102100035654 Cathepsin S Human genes 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
235000021538 Chard Nutrition 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108090000227 Chymases Proteins 0.000 description 1
102000003858 Chymases Human genes 0.000 description 1
241000710777 Classical swine fever virus Species 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108010010256 Dietary Proteins Proteins 0.000 description 1
102000015781 Dietary Proteins Human genes 0.000 description 1
102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
102100031245 Disks large-associated protein 2 Human genes 0.000 description 1
108050003184 Disks large-associated protein 2 Proteins 0.000 description 1
108700022174 Drosophila Son of Sevenless Proteins 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
108700033311 EC 3.4.23.16 Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
108091006109 GTPases Proteins 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000031995 Gorlin syndrome Diseases 0.000 description 1
102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101710176455 H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000724675 Hepatitis E virus Species 0.000 description 1
102400000777 His3-(20-43)-peptide Human genes 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101100168465 Homo sapiens CAPNS1 gene Proteins 0.000 description 1
101000867692 Homo sapiens Calpain-2 catalytic subunit Proteins 0.000 description 1
101000867715 Homo sapiens Calpain-3 Proteins 0.000 description 1
101000793671 Homo sapiens Calpain-6 Proteins 0.000 description 1
101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
101000898505 Homo sapiens Histatin-3 Proteins 0.000 description 1
101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Chemical group OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
241000710921 Infectious pancreatic necrosis virus Species 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
108010092694 L-Selectin Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
102000003843 Metalloendopeptidases Human genes 0.000 description 1
108090000131 Metalloendopeptidases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108010070047 Notch Receptors Proteins 0.000 description 1
102000005650 Notch Receptors Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
208000004286 Osteochondrodysplasias Diseases 0.000 description 1
201000000023 Osteosclerosis Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108010069873 Patched Receptors Proteins 0.000 description 1
102000008880 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Human genes 0.000 description 1
108050000823 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
108010068086 Polyubiquitin Proteins 0.000 description 1
102100037935 Polyubiquitin-C Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
101710178372 Prolyl endopeptidase Proteins 0.000 description 1
229940079156 Proteasome inhibitor Drugs 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
102100028680 Protein patched homolog 1 Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
101150040459 RAS gene Proteins 0.000 description 1
101150076031 RAS1 gene Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
101000721481 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Succinyl-diaminopimelate desuccinylase Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102000003667 Serine Endopeptidases Human genes 0.000 description 1
108090000083 Serine Endopeptidases Proteins 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000251131 Sphyrna Species 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101150109894 TGFA gene Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
101710097834 Thiol protease Proteins 0.000 description 1
102000002933 Thioredoxin Human genes 0.000 description 1
LJJKNPQAGWVLDQ-UHFFFAOYSA-N Thiorphan Chemical compound OC(=O)CNC(=O)C(CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-UHFFFAOYSA-N 0.000 description 1
108010036928 Thiorphan Proteins 0.000 description 1
102000007983 Threonine endopeptidases Human genes 0.000 description 1
108030005531 Threonine endopeptidases Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108060005989 Tryptase Proteins 0.000 description 1
102000001400 Tryptase Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
108700010756 Viral Polyproteins Proteins 0.000 description 1
108700022715 Viral Proteases Proteins 0.000 description 1
101000752225 Xenopus laevis Low density lipoprotein receptor adapter protein 1-A Proteins 0.000 description 1
101710204001 Zinc metalloprotease Proteins 0.000 description 1
UUMKQZVEZSXWBY-HNNXBMFYSA-N [[(1s)-2-(4-phenylphenyl)-1-(2h-tetrazol-5-yl)ethyl]amino]methylphosphonic acid Chemical compound C([C@H](NCP(O)(=O)O)C1=NNN=N1)C(C=C1)=CC=C1C1=CC=CC=C1 UUMKQZVEZSXWBY-HNNXBMFYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
239000007801 affinity label Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000012637 allosteric effector Substances 0.000 description 1
108010052590 amastatin Proteins 0.000 description 1
QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001896 anti-amyloidogenic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000001908 autoinhibitory effect Effects 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229910052614 beryl Inorganic materials 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
235000010633 broth Nutrition 0.000 description 1
SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
102000036109 cAMP binding proteins Human genes 0.000 description 1
108091010966 cAMP binding proteins Proteins 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
201000011529 cardiovascular cancer Diseases 0.000 description 1
210000003321 cartilage cell Anatomy 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
241000902900 cellular organisms Species 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000006364 cellular survival Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
210000001771 cumulus cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000021245 dietary protein Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
235000021186 dishes Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002242 embryoid body Anatomy 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000004212 embryonic organizer Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000004039 endoderm cell Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
102000036444 extracellular matrix enzymes Human genes 0.000 description 1
108091007167 extracellular matrix enzymes Proteins 0.000 description 1
210000001097 facial muscle Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Chemical group 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
230000021369 gonad morphogenesis Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
KSXBMTJGDUPBBN-VPKNIDFUSA-N histatin 5 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 KSXBMTJGDUPBBN-VPKNIDFUSA-N 0.000 description 1
208000009624 holoprosencephaly Diseases 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000010039 intracellular degradation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
238000001038 ionspray mass spectrometry Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000003674 kinase activity assay Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000982 limb bud Anatomy 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000004777 loss-of-function mutation Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000007347 lysosomal proteolysis Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000023508 male gonad development Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108010058731 nopaline synthase Proteins 0.000 description 1
210000003458 notochord Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000005305 organ development Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
210000001696 pelvic girdle Anatomy 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008884 pinocytosis Effects 0.000 description 1
230000028742 placenta development Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229930001119 polyketide Natural products 0.000 description 1
125000000830 polyketide group Chemical group 0.000 description 1
229930001118 polyketide hybrid Natural products 0.000 description 1
125000003308 polyketide hybrid group Chemical group 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
108010000222 polyserine Proteins 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
108091005629 prenylated proteins Proteins 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
108010029690 procollagenase Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
201000002212 progressive supranuclear palsy Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229960003581 pyridoxal Drugs 0.000 description 1
235000008164 pyridoxal Nutrition 0.000 description 1
239000011674 pyridoxal Substances 0.000 description 1
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
229960001327 pyridoxal phosphate Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
101150079601 recA gene Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008886 response to retinoic acid Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
230000009645 skeletal growth Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000002689 soil Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000012256 transgenic experiment Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
108010002164 tyrosine receptor Proteins 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000004862 vasculogenesis Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
238000003158 yeast two-hybrid assay Methods 0.000 description 1
238000001086 yeast two-hybrid system Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Wood Science & Technology (AREA)
Pain & Pain Management (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Obesity (AREA)
Hematology (AREA)

CA002408105A 2000-05-04 2001-05-04 Novel proteases Abandoned CA2408105A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20187900P	2000-05-04	2000-05-04
US60/201,879		2000-05-04
PCT/US2001/014431 WO2001083782A2 (en)	2000-05-04	2001-05-04	Novel proteases

Publications (1)

Publication Number	Publication Date
CA2408105A1 true CA2408105A1 (en)	2001-11-08

Family

ID=22747660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002408105A Abandoned CA2408105A1 (en)	2000-05-04	2001-05-04	Novel proteases

Country Status (6)

Country	Link
EP (1)	EP1294901A2 (de)
JP (1)	JP2004504812A (de)
AU (1)	AU2001259473A1 (de)
CA (1)	CA2408105A1 (de)
HK (1)	HK1054571A1 (de)
WO (1)	WO2001083782A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030096391A1 (en) *	2000-12-22	2003-05-22	Millennium Pharmaceuticals, Inc.	17903, a novel human aminopeptidase and uses therefor
US6683165B1 (en)	1999-04-13	2004-01-27	Genome Therapeutics Corporation	Human gene relating to respiratory diseases and obesity
US7034132B2 (en)	2001-06-04	2006-04-25	Anderson David W	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20020115842A1 (en) *	2000-09-29	2002-08-22	Friddle Carl Johan	Novel human proteases and polynucleotides encoding the same
ES2310527T3 (es)	1999-11-19	2009-01-16	Solvay Pharmaceuticals B.V.	Enzimas humanas de la familia de las metaloproteasas.
EP1134286A3 (de) *	2000-03-14	2003-05-02	Pfizer Products Inc.	Adamts Polypeptide, dafür kodierende Nukleinsaüren und deren Verwendung
CA2405078A1 (en) *	2000-04-13	2001-10-25	Tim Keith	Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
DE10031932A1 (de) *	2000-06-30	2002-01-10	Basf Ag	Calpain-Protease 12
WO2002010406A2 (en) *	2000-07-28	2002-02-07	Immunex Corporation	Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
GB0020345D0 (en) *	2000-08-17	2000-10-04	Glaxo Group Ltd	Protein
AU2001288339B2 (en) *	2000-08-22	2005-09-29	Lexicon Pharmaceuticals, Inc.	Novel human proteases and polynucleotides encoding the same
AU2002218160A1 (en) *	2000-09-11	2002-03-22	Bayer Aktiengesellschaft	Regulation of human carboxypeptidase-like enzyme
AU2001289886A1 (en) *	2000-09-20	2002-04-02	Bayer Aktiengesellschaft	Regulation of human adam-ts 1 precursor-like protein
WO2002026948A2 (en) *	2000-09-25	2002-04-04	Millennium Pharmaceuticals, Inc.	55054, a human metalloprotease and uses therefor
WO2002026955A2 (en) *	2000-09-29	2002-04-04	Lexicon Genetics Incorporated	Human proteases and polynucleotides encoding the same
WO2002029026A2 (en) *	2000-10-04	2002-04-11	Lexicon Genetics Incorporated	Human proteases and polynucleotides encoding the same
WO2002033087A2 (en) *	2000-10-17	2002-04-25	Curagen Corporation	Proteins and nucleic acids encoding same
US6689599B1 (en) *	2000-10-20	2004-02-10	Genetics Institute, Llc	Aggrecanase molecules
EP1407018A2 (de) *	2000-10-26	2004-04-14	Curagen Corporation	Menschliche proteine, dafür kodierende polynukleotide und verfahren zu ihrer verwendung
US20020119555A1 (en) *	2000-12-22	2002-08-29	Rajasehkar Bandaru	53014, a human metalloprotease family member and uses therefor
ATE353961T1 (de) *	2000-12-25	2007-03-15	Astellas Pharma Inc	Neue protease
US6903201B2 (en)	2001-01-05	2005-06-07	Curagen Corporation	Proteins and nucleic acids encoding same
WO2002057461A2 (en) *	2001-01-18	2002-07-25	Bayer Aktiengesellschaft	Regulation of human adam-ts-like zinc metalloprotease
WO2002088303A2 (en) *	2001-04-03	2002-11-07	Bristol-Myers Squibb Company	Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US7034134B2 (en) *	2001-04-26	2006-04-25	Bristol-Myers Squibb Company	Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
JP2005506833A (ja) *	2001-06-04	2005-03-10	キュラジェンコーポレイション	抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
JP2004533848A (ja)	2001-07-10	2004-11-11	バイエル・ヘルスケア・アクチェンゲゼルシャフト	ヒトアミノペプチダーゼｎの調節
WO2003012038A2 (en)	2001-07-27	2003-02-13	Wyeth	Aggrecanase molecules
CA2457915A1 (en) *	2001-08-22	2003-03-06	Lexicon Genetics Incorporated	Novel human proteases and polynucleotides encoding the same
WO2003027282A1 (en) *	2001-09-24	2003-04-03	Daiichi Fine Chemical Co., Ltd.	Adamts-15, -16, -17, -18 and -19
WO2003042379A2 (en) *	2001-11-13	2003-05-22	Universite De Liege	A new disintegrin and metalloproteinase with thrombospondin type i repeats polynucleotide and its encoded polypeptide
AU2002360832A1 (en) *	2001-12-31	2003-07-24	Wyeth	Aggrecanase molecules
JP2005515779A (ja) *	2002-01-31	2005-06-02	ワイス	アグレカナーゼ分子
WO2003089644A1 (fr) *	2002-04-19	2003-10-30	Riken	Nouvelles proteines et adn codant pour elles
US20060014931A1 (en) *	2002-06-20	2006-01-19	Masayoshi Takeda	Novel promoter
NL1022371C2 (nl) *	2003-01-13	2003-11-18	Hoffmann La Roche	Nieuwe metallo-proteasen met trombospondine domeinen en daarvoor coderende nucle´nezuur samenstellingen.
WO2004073657A2 (en) *	2003-02-19	2004-09-02	Protein Design Labs, Inc.	Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
US20070202567A1 (en) *	2003-09-27	2007-08-30	Bayer Healthcare Ag	Diagnostics And Therapeutics For Diseases Associated With Arginyl Aminopeptidase Rnpep (Rnpep)
US20080248462A1 (en) *	2003-10-21	2008-10-09	Baayer Healhcare Ag	Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1)
US7892750B1 (en) *	2004-12-23	2011-02-22	University Of Notre Dame Du Lac	Cathepsin E as a marker of colon cancer
JP5532216B2 (ja) *	2009-12-28	2014-06-25	国立大学法人埼玉大学	乳癌の検出方法
CN114075544A (zh) *	2020-08-21	2022-02-22	复旦大学附属华山医院	基于超滤离心制备去泛素红细胞制品的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0123928A3 (de) *	1983-03-31	1986-02-05	Codon Genetic Engineering Laboratories	Rekombinantes DNS, das für ein Milchgerinnungsaktivität aufweisendes Peptid kodiert
WO1998031818A2 (en) *	1997-01-21	1998-07-23	Human Genome Sciences, Inc.	Tace-like and matrilysin-like polypeptides
AU3622600A (en) *	1999-03-08	2000-09-28	Neurocrine Biosciences, Inc.	Metalloproteinases and methods of use therefor
US6383780B1 (en) *	1999-11-19	2002-05-07	Millennium Pharmaceuticals, Inc.	2786, a novel human aminopeptidase
EP1292684A2 (de) *	2000-06-16	2003-03-19	Incyte Genomics, Inc.	Protease

2001
- 2001-05-04 JP JP2001580389A patent/JP2004504812A/ja not_active Withdrawn
- 2001-05-04 CA CA002408105A patent/CA2408105A1/en not_active Abandoned
- 2001-05-04 HK HK03106801.3A patent/HK1054571A1/zh unknown
- 2001-05-04 AU AU2001259473A patent/AU2001259473A1/en not_active Abandoned
- 2001-05-04 EP EP01933003A patent/EP1294901A2/de not_active Withdrawn
- 2001-05-04 WO PCT/US2001/014431 patent/WO2001083782A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2001083782A3 (en)	2003-01-23
WO2001083782A2 (en)	2001-11-08
JP2004504812A (ja)	2004-02-19
HK1054571A1 (zh)	2003-12-05
EP1294901A2 (de)	2003-03-26
AU2001259473A1 (en)	2001-11-12

Legal Events

Date	Code	Title	Description
2006-05-04	FZDE	Discontinued
2023-05-26	FZDE	Discontinued	Effective date: 20060504

Publication	Publication Date	Title
WO2001083782A2 (en)	2001-11-08	Novel proteases
US20050287546A1 (en)	2005-12-29	Novel proteases
Velasco et al.	2002	Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins
KR101126423B1 (ko)	2012-07-11	보체 활성화를 억제하는 변형된 프로테아제
CN101517074B (zh)	2013-07-03	蛋白酶筛选方法及由此鉴别的蛋白酶
SG175602A1 (en)	2011-11-28	Protease screening methods and proteases identified thereby
US6521436B1 (en)	2003-02-18	Nucleic acids encoding aggrecan degrading metallo proteases
US7078217B2 (en)	2006-07-18	Aggrecanase molecules
WO2001046394A2 (en)	2001-06-28	Mammalian protein phosphatases
JPH10210982A (ja)	1998-08-11	新規なタンパク質
EP1084259B1 (de)	2008-05-28	Corin, eine serinprotease
US20040063107A1 (en)	2004-04-01	Novel proteases
US20040157306A1 (en)	2004-08-12	Mammalian protein phosphatases
US20040132155A1 (en)	2004-07-08	Mammalian protein phosphatases
US6806075B1 (en)	2004-10-19	Corin, a serine protease
US20020090703A1 (en)	2002-07-11	Mammalian protein phosphatases
CA2350165C (en)	2011-12-13	Novel serine protease bssp6
US20040132158A1 (en)	2004-07-08	Human peptidases
US20050026255A1 (en)	2005-02-03	Corin, a serine protease
CA2616940C (en)	2011-08-09	Novel serine protease bssp2
US20020197703A1 (en)	2002-12-26	65552, a human matrix metalloproteinase and uses therefor
US20030008291A1 (en)	2003-01-09	Novel DNA repair enzymes, nucleic acids encoding DNA repair enzymes and methods of using them
EP1446487A1 (de)	2004-08-18	Säuger-protein phosphatasen
CA2395093A1 (en)	2001-06-28	Mammalian protein phosphatases
EP1299525A2 (de)	2003-04-09	Säugetier proteinphosphatasen